GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma [0.03%]
GSTA1介导了对奥希替尼的耐受性，并提供了克服EGFR突变肺腺癌药物容忍型持续存在的策略
Xiaoshen Zhang,Yaokai Wen,Fengying Wu et al.
Xiaoshen Zhang et al.
The generation of drug-tolerant persister (DTP) cancer cells remains a major challenge for lung adenocarcinoma (LUAD) patients treated with EGFR-tyrosine kinase inhibitors (TKIs), as these cells eventually lead to drug resistance and diseas...
Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927] [0.03%]
“JCOG2007(NIPPON)Ⅲ期临床试验的辅助生物标志物研究：晚期NSCLC化疗免疫治疗后肠道微生态的变化”校正公告
Taiki Hakozaki,Kentaro Tanaka,Yoshimasa Shiraishi et al.
Taiki Hakozaki et al.
A Response to Letter to the Editor: "Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study" [0.03%]
论著答复：“肺癌筛查、过诊断及医疗服务利用的全国人群队列研究”
So Yeon Kim,Gerard A Silvestri,Young Sik Park
So Yeon Kim
Screening for Lung Cancer, Overdiagnosis, and Health Care Utilization: A Nationwide Population-Based Study [0.03%]
肺癌筛查、过诊断及医疗利用的全国人群-based研究
Defeng Zhao,Wenze Li,Wenya Li
Defeng Zhao
Comorbidities in Lung Cancer Screening: A Key to Finding the Right Spot or Opening Pandora's Box? [0.03%]
肺癌筛查中的合并症：找到正确的定位还是打开潘多拉的盒子？
Sebastien Gendarme,Christos Chouaid,Edwin Ostrin
Sebastien Gendarme
Exploring the Impact of Comorbidities on Lung Cancer Screening Mortality Benefits: Insights and Suggestions for Methodological Enhancement [0.03%]
探索共病对肺癌筛查降低死亡率效益的影响：方法改进的启示与建议
Yimao Wu,Yalun Liang,Jintao Liang
Yimao Wu
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups" [0.03%]
致《编辑部来信》：“METex14突变NSCLC亚组中Amivantamab疗效的持续获益超越应答？”的一封回信
Matthew G Krebs,Byoung Chul Cho,Priya Kim et al.
Matthew G Krebs et al.
Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups [0.03%]
超越响应的持久获益：重新解读Amivantamab在MET外显子14跳变NSCLC亚组中的疗效
Tsai Ling Ting,Shiuan-Chih Chen
Tsai Ling Ting
Critical Considerations for the Evaluation of Lazertinib in NSCLC With Uncommon EGFR Mutations [0.03%]
罕见EGFR突变NSCLC患者中评价Lazertinib的几个关键问题
Xuefan Zeng,Qian Guo
Xuefan Zeng